| __timestamp | Soleno Therapeutics, Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 2917513 | 2999000 |
| Thursday, January 1, 2015 | 7878291 | 10393000 |
| Friday, January 1, 2016 | 8366794 | 15994000 |
| Sunday, January 1, 2017 | 6610381 | 26975000 |
| Monday, January 1, 2018 | 6556000 | 39509000 |
| Tuesday, January 1, 2019 | 6930000 | 48869000 |
| Wednesday, January 1, 2020 | 8758000 | 42510000 |
| Friday, January 1, 2021 | 10806000 | 46105000 |
| Saturday, January 1, 2022 | 9844000 | 50513000 |
| Sunday, January 1, 2023 | 13481000 | 51292000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Soleno Therapeutics, Inc. and Wave Life Sciences Ltd. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Wave Life Sciences consistently outpaced Soleno, with its SG&A expenses peaking at approximately $51 million in 2023, a staggering 70% increase from 2014. In contrast, Soleno's expenses grew by about 360%, reaching $13 million in 2023. This divergence highlights Wave's aggressive expansion strategy compared to Soleno's more conservative approach. The data suggests that while both companies are investing in growth, Wave Life Sciences is committing significantly more resources to its administrative and operational functions. This could indicate a broader market strategy or a response to increased competition. Understanding these patterns provides valuable insights into each company's strategic priorities.
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Soleno Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for GSK plc and Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Lantheus Holdings, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Wave Life Sciences Ltd.
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Soleno Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Mesoblast Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.